TRAPHACO JOINT STOCK COMPANY

Traphaco Joint Stock Company (Công ty Cổ phần Traphaco) is one of Vietnam’s most distinguished pharmaceutical manufacturers, widely recognized for its leadership in herbal and traditional medicine. With more than 50 years of operation, the company has successfully merged Eastern medical heritage with Western production technologies to become a trusted name in both urban and rural markets. Traphaco is legally registered under business ID and tax code 0100108656, and is listed on the Ho Chi Minh Stock Exchange (HOSE) with the ticker TRA.

Headquartered at Lane 15, Ngoc Hoi Street, Hoang Liet Ward, Hoang Mai District, Hanoi, Traphaco operates as a public joint stock company with a diverse shareholder structure, including State Capital Investment Corporation (35.67%), Magbi Fund Limited (25%), and other foreign and domestic investors. Its executive leadership includes Chairman Mr. Chung Ji Kwang, a South Korean national, and General Director Mr. Tran Tuc Ma, supported by a capable management team. The company employs 1,670 staff across Vietnam and maintains GMP-WHO certified production facilities in Hanoi and Hung Yen.

In the fiscal year ending December 31, 2024, Traphaco recorded total revenue of USD 96.43 million and a net profit of USD 10.57 million, despite a 9.78% decline in profit year-over-year. The company held total assets of USD 89.11 million and owner’s equity of USD 62.97 million, reflecting strong financial stability and conservative capital use. Traphaco also reported working capital of USD 39.35 million, positioning it to comfortably fund operations and product expansion.

Traphaco’s strategic focus lies in herbal medicine, OTC drugs, and wellness products, which continue to appeal to Vietnam’s aging population and growing demand for preventive care. The company has embraced digital transformation to modernize its supply chain and improve customer interaction, and it actively pursues research collaborations to strengthen its R&D capabilities. Its broad distribution network, innovation in dosage forms, and dedication to sustainable sourcing make it a model for Vietnam’s herbal pharmaceutical sector.

For stakeholders seeking reliable data on Vietnam's pharmaceutical leaders, Vanguard Business Information LLC (VBI) provides detailed reports, credit profiles, and risk evaluations, including for Traphaco. With a long-standing reputation, strong financial discipline, and a future-oriented business model, Traphaco is well-positioned to sustain its leadership in Vietnam’s health and wellness industry.